Journal of Antivirals & Antiretrovirals
Open Access
ISSN: 1948-5964
+44 1300 500008
ISSN: 1948-5964
+44 1300 500008
Uladzimir Karniychuk, David Banner, Stephane Paquette, Alberto Leon and David Kelvin
University Health Network, Canada
Posters-Accepted Abstracts: J Antivir Antiretrovir
Most patients with severe influenza disease seek hospital care many days after initial onset of symptoms, limiting the effective use of antivirals. The main goal in the present study was to compare therapeutic effects of delayed intrapulmonary and intramuscular delivery of peramivir on severe infection outcome. To recapitulate late stage, lower respiratory tract infection, aged ferrets were inoculated intrapulmonary with 106 EID50 influenza A/California/07/2009 H1N1. Peramivir was delivered at 3 and 5 dpi intrapulmonary (PP) or intramuscularly (PM). A group of animals was administrated intrapulmonary with only a vehicle (saline) for control purposes (VP). All animals in the VP group were euthanized due to severity of the diseases at 8 dpi. Survival in the PP group (75%) was 25% higher than in the PM group. In comparison to the control VP group, intrapulmonary and intramuscular peramivir administration efficiently reduced viral titers in nasal washes. At 5 dpi, viral titers in lungs from the PP group were lower than in samples from other groups (PP ��? mean 3.37 TCID50/ml; PM ��? mean 4.55 TCID50/ml; VP ��? mean 6.44 TCID50/ml). Reduced area of lung surfaces with pathology were observed in the PP group (PP ��? mean 19%; PM ��? mean 40%; VP ��? mean 72%). Microscopic lesions associated with severe disruption of the lung architecture were found only in ferrets from the VP group and one ferret from the PM group. To summarize, delayed intrapulmonary peramivir administration in aged ferrets has benefits to recovery from severe influenza infection in comparison to delayed intramuscular Peramivir administration.
Uladzimir Karniychuk has obtained a DVM degree with Honours from Vitebsk State Academy of Veterinary Medicine, Belarus. He has completed his PhD in the Laboratory of Virology, Ghent University, Belgium. At present, he is a Post-doctoral Researcher in University Health Network, Canada. He has published 15 papers in well-recognized international journals and obtained several highly competitive international and national fellowships (three PhD grants, CIHR Postdoctoral Fellowship) and awards (Toronto General Research Institute Postdoctoral Fellowship Award and six young scientist travel/poster awards).
Email: vova.korniychuk@gmail.com